Structure Therapeutics American Stock Total Asset
| GPCR Stock | 30.10 2.61 7.98% |
Structure Therapeutics American fundamentals help investors to digest information that contributes to Structure Therapeutics' financial success or failures. It also enables traders to predict the movement of Structure Stock. The fundamental analysis module provides a way to measure Structure Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Structure Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Total Assets | 482 M | 506.1 M |
Structure | Total Asset |
Structure Therapeutics American Company Total Asset Analysis
Structure Therapeutics' Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Structure Therapeutics Total Asset | 482.02 M |
Most of Structure Therapeutics' fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Structure Therapeutics American is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Structure Total Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Structure Therapeutics is extremely important. It helps to project a fair market value of Structure Stock properly, considering its historical fundamentals such as Total Asset. Since Structure Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Structure Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Structure Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Structure Total Asset Historical Pattern
Today, most investors in Structure Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Structure Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Structure Therapeutics total asset as a starting point in their analysis.
Structure Therapeutics Total Asset |
| Timeline |
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Structure Total Assets
Total Assets |
|
Based on the latest financial disclosure, Structure Therapeutics American has a Total Asset of 482.02 M. This is 93.59% lower than that of the Biotechnology sector and 75.6% lower than that of the Health Care industry. The total asset for all United States stocks is 98.36% higher than that of the company.
Structure Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Structure Therapeutics' direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Structure Therapeutics could also be used in its relative valuation, which is a method of valuing Structure Therapeutics by comparing valuation metrics of similar companies.Structure Therapeutics is currently under evaluation in total asset category among its peers.
Structure Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Structure Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Structure Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Structure Fundamentals
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.13 | ||||
| Current Valuation | 812.65 M | ||||
| Shares Outstanding | 57.26 M | ||||
| Shares Owned By Insiders | 4.84 % | ||||
| Shares Owned By Institutions | 95.16 % | ||||
| Number Of Shares Shorted | 10.44 M | ||||
| Price To Book | 1.92 X | ||||
| EBITDA | (102.46 M) | ||||
| Net Income | (89.62 M) | ||||
| Total Debt | 5.45 M | ||||
| Book Value Per Share | 9.76 X | ||||
| Cash Flow From Operations | (79.49 M) | ||||
| Short Ratio | 15.69 X | ||||
| Earnings Per Share | (2.16) X | ||||
| Target Price | 85.82 | ||||
| Number Of Employees | 136 | ||||
| Market Capitalization | 1.72 B | ||||
| Total Asset | 482.02 M | ||||
| Retained Earnings | (206.57 M) | ||||
| Working Capital | 448.87 M | ||||
| Net Asset | 482.02 M |
About Structure Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Structure Therapeutics American's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Structure Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Structure Therapeutics American based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Structure Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Structure Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Structure Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Structure Stock
Moving against Structure Stock
| 0.43 | MDGL | Madrigal Pharmaceuticals | PairCorr |
| 0.43 | KEP | Korea Electric Power | PairCorr |
| 0.31 | RNXT | RenovoRx | PairCorr |
The ability to find closely correlated positions to Structure Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Structure Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Structure Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Structure Therapeutics American to buy it.
The correlation of Structure Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Structure Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Structure Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Structure Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Structure Stock Analysis
When running Structure Therapeutics' price analysis, check to measure Structure Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Structure Therapeutics is operating at the current time. Most of Structure Therapeutics' value examination focuses on studying past and present price action to predict the probability of Structure Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Structure Therapeutics' price. Additionally, you may evaluate how the addition of Structure Therapeutics to your portfolios can decrease your overall portfolio volatility.